NanoRepro AG Asset Resilience Ratio

Latest as of June 2025: 19.19%

NanoRepro AG asset resilience ratio. NanoRepro AG (NN6) has an Asset Resilience Ratio of 19.19% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of NanoRepro AG to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€7.29 Million
≈ $8.52 Million USD Cash + Short-term Investments

Total Assets

€37.99 Million
≈ $44.42 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of NanoRepro AG (2010–2024)

Asset resilience ratio of NanoRepro AG from 2010 to 2024. This chart shows how NanoRepro AG's Asset Resilience Ratio has changed over time. Read debt load of NanoRepro AG for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down NanoRepro AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NanoRepro AG total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €7.29 Million 19.19%
Short-term Investments €0.00 0%
Total Liquid Assets €7.29 Million 19.19%

Asset Resilience Insights

  • Good Liquidity Position: NanoRepro AG maintains a healthy 19.19% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

NanoRepro AG Industry Peers by Asset Resilience Ratio

Compare NanoRepro AG's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Lonza Group AG
SW:LONN
Diagnostics & Research 3.04%
Revvity Inc.
NYSE:RVTY
Diagnostics & Research 0.00%
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
Diagnostics & Research 13.43%
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
Diagnostics & Research 0.14%
Cowealth Medical China Co.Ltd.
SHG:603122
Diagnostics & Research 2.25%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Prodia Widyahusada Tbk PT
JK:PRDA
Diagnostics & Research 7.82%
Scope Fluidics SA
WAR:SCP
Diagnostics & Research 16.51%

NanoRepro AG Asset Resilience Ratio by Year (2010–2024)

NanoRepro AG asset resilience ratio by year from 2010 to 2024. The table below shows the annual Asset Resilience Ratio data for NanoRepro AG.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 23.31% €9.10 Million
≈ $10.64 Million
€39.03 Million
≈ $45.62 Million
-26.43pp
2023-12-31 49.74% €20.62 Million
≈ $24.11 Million
€41.46 Million
≈ $48.47 Million
-13.44pp
2022-12-31 63.18% €31.26 Million
≈ $36.55 Million
€49.48 Million
≈ $57.84 Million
+27.78pp
2021-12-31 35.40% €28.02 Million
≈ $32.76 Million
€79.15 Million
≈ $92.53 Million
+24.98pp
2020-12-31 10.42% €1.16 Million
≈ $1.36 Million
€11.17 Million
≈ $13.06 Million
-4.93pp
2019-12-31 15.35% €737.15K
≈ $861.81K
€4.80 Million
≈ $5.62 Million
-15.13pp
2018-12-31 30.48% €1.77 Million
≈ $2.07 Million
€5.81 Million
≈ $6.79 Million
+17.90pp
2017-12-31 12.58% €528.05K
≈ $617.35K
€4.20 Million
≈ $4.91 Million
-2.51pp
2016-12-31 15.09% €530.12K
≈ $619.77K
€3.51 Million
≈ $4.11 Million
+14.98pp
2010-12-31 0.11% €2.15K
≈ $2.52K
€1.94 Million
≈ $2.27 Million
--
pp = percentage points

About NanoRepro AG

XETRA:NN6 Germany Diagnostics & Research
Market Cap
$23.15 Million
€19.80 Million EUR
Market Cap Rank
#24603 Global
#2127 in Germany
Share Price
€1.57
Change (1 day)
-2.79%
52-Week Range
€1.38 - €2.29
All Time High
€17.14
About

NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preve… Read more